デフォルト表紙
市場調査レポート
商品コード
1664231

インドの陽子線治療市場:製品タイプ別、適応症別、設定タイプ別、エンドユーザー別、地域別、機会、予測、2018年~2032年

India Proton Therapy Market Assessment, By Product Type, By Indications, By Setup Type, By End-user, By Region, Opportunities and Forecast, FY2018-FY2032F


出版日
ページ情報
英文 128 Pages
納期
3~5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
インドの陽子線治療市場:製品タイプ別、適応症別、設定タイプ別、エンドユーザー別、地域別、機会、予測、2018年~2032年
出版日: 2025年02月28日
発行: Market Xcel - Markets and Data
ページ情報: 英文 128 Pages
納期: 3~5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

インドの陽子線治療の市場規模は、2025年から2032年にかけて10.00%のCAGRで拡大し、2024年の2,127万米ドルから2032年には4,560万米ドルに増加すると予測されています。インドの陽子線治療市場は、がん罹患率の上昇、医療費の増加、がん施設の増加、精密放射線技術の進歩によって推進されています。さらに、政府プログラム、認知度の向上、国際ヘルスケアリーダーとの提携も採用を後押ししています。また、治療費の値ごろ感、医療ツーリズム、より安全で的を絞ったがん治療への需要の高まりも市場拡大を後押ししています。

インドでは、ライフスタイルの変化、環境暴露、人口の高齢化によって罹患率が上昇しており、がんは公衆衛生の主要な関心事として浮上しています。この懸念に伴い、政府と民間部門は国家プログラム、早期発見プログラム、治療へのアクセス改善といった形でヘルスケア・インフラを強化しています。全国各地にがん治療センターを新設することは、患者の治療向上に不可欠です。2024年12月、政府は高知に新たながんセンターを開設し、コーチンがん研究センター(CCRC)として設立することを宣言しました。このセンターは2025年2月から5月の間に稼動する予定です。さらに、エルナクラムにある政府医科大学病院(MCH)の専門棟は、2025年4月までに完成する見込みです。

さらに、研究機関や世界の保健当局と病院が提携することで、最新の腫瘍学技術のイントロダクションが進んでいます。患者や医療関係者の意識の高まりとともに、治療選択肢の改善に対する需要の高まりが、インドにおける陽子線治療の開発を加速させています。高精度で低毒性のがん治療を提供することに重点を置く陽子線治療市場は、長期的な成長の態勢を整えており、大きな投資機会、インフラ開拓、患者の転帰改善の可能性を秘めています。

当レポートでは、インドの陽子線治療市場について調査し、市場の概要とともに、製品タイプ別、適応症別、設定タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 インドの陽子線治療市場の見通し、2018年~2032年

  • 市場規模の分析と予測
  • 市場シェア分析と予測
  • 市場マップ分析、2024年
    • 製品タイプ別
    • 適応症別
    • 設定タイプ別
    • エンドユーザー別
    • 地域別

第5章 需要供給分析

第6章 輸出入の分析

第7章 バリューチェーン分析

第8章 ポーターのファイブフォース分析

第9章 PESTLE分析

第10章 価格分析

第11章 市場力学

第12章 市場の動向と発展

第13章 規制枠組みとイノベーション

第14章 特許の情勢

第15章 ケーススタディ

第16章 競合情勢

  • 市場リーダートップ5の競合マトリックス
  • 参入企業トップ5のSWOT分析
  • 市場の主要参入企業トップ5の情勢
    • Ion Beam Applications SA (IBA)
    • Varian Medical Systems International India Pvt. Ltd.
    • Mitsubishi Electric Corporation
    • Hitachi Ltd.
    • Elekta Medical Systems India Pvt. Ltd.
    • Mevion Medical Systems, Inc.
    • Optivus Proton Therapy, Inc.
    • ProTom International
    • Provision Solutions, LLC
    • Sumitomo Heavy Industries Ltd.

第17章 戦略的提言

第18章 調査会社について・免責事項

図表

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. India Proton Therapy Market, By Value, In USD Million, FY2018-FY2032F
  • Figure 2. India Proton Therapy Market, By Volume, In Million Units, FY2018-FY2032F
  • Figure 3. India Proton Therapy Market Share (%), By Product Type, FY2018-FY2032F
  • Figure 4. India Proton Therapy Market Share (%), By Indications, FY2018-FY2032F
  • Figure 5. India Proton Therapy Market Share (%), By Setup Type, FY2018-FY2032F
  • Figure 6. India Proton Therapy Market Share (%), By End-user, FY2018-FY2032F
  • Figure 7. India Proton Therapy Market Share (%), By Region, FY2018-FY2032F
  • Figure 8. By Product Type Map-Market Size (USD Million) & Growth Rate (%), FY2024
  • Figure 9. By Indications Map-Market Size (USD Million) & Growth Rate (%), FY2024
  • Figure 10. By Setup Type Map-Market Size (USD Million) & Growth Rate (%), FY2024
  • Figure 11. By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2024
  • Figure 12. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2024
目次
Product Code: MX12778

India proton therapy market is projected to grow at a CAGR of 10.00% from FY2025 to FY2032, increasing from USD 21.27 million in FY2024 to USD 45.60 million by FY2032. The proton therapy market in India is propelled by the rising cancer incidence, increased healthcare expenditure, growing cancer facilities, and advances in precision radiation technology. Furthermore, government programs, growing awareness, and partnerships with international healthcare leaders also drive adoption. Growing affordability, medical tourism, and demand for safer, targeted cancer treatment also support the market expansion.

Cancer is emerging as a major public health concern in India, with a rising incidence due to lifestyle changes, environmental exposures, and the aging of the population. In line with this concern, the government and private sectors are reinforcing healthcare infrastructure in the form of national programs, early detection programs, and better access to treatment. The establishment of new cancer treatment centers throughout the country is vital to the improvement of patient care. In December 2024, the government declared the opening of a new cancer center in Kochi to be established as the Cochin Cancer Research Centre (CCRC). This center is likely to be operational between February and May 2025. Furthermore, a specialized block of the Government Medical College Hospital (MCH) in Ernakulam is likely to be ready by April 2025.

Moreover, hospital partnerships with research institutions and global health authorities are assisting in the introduction of the newest oncology technologies. Increasing demand for improved treatment alternatives, along with increasing patient and medical professional awareness, is assisting in accelerating the development of proton therapy in India. With an emphasis on the provision of high-precision, low-toxicity cancer treatment, the proton therapy market is poised for long-term growth, with the potential to offer significant investment opportunities, infrastructure development, and improved patient outcomes in the country.

Increasing Research Activities Supports Market Expansion

India is developing its cancer research landscape by strengthening their R&D sector, with government efforts, research collaborations, and more funding. As the number of cancer patients grows, measures are being taken to enhance cancer management and treatment. One of the notable advancements is India's achievement in proton therapy accessibility. For example, in May 2023, a proton beam facility has been established at the Tata Memorial Centre's Kharghar campus, the first one in the public sector. The purpose is to facilitate treatment conveniently for cancer patients by offering free treatment to some needy patients while offering subsidized prices to other cancer patients. This is an effort to manage the rising numbers of cancer patients in India. In September 2024, Tata Memorial Centre (TMC) announced in-house research to maximize the utility of proton beam therapy, a cutting-edge radiation therapy for pediatric and adult cancers. TMC's Advanced Centre for Treatment Research & Education in Cancer (ACTREC) will collaborate with international researchers and assess which patient groups benefit the most from proton therapy. Such efforts in the country present promising expansion potential for the proton therapy market.

Rising Public Awareness Campaigns Boosting Market Growth

Rising public awareness of cancer and the treatment process is considerably propelling the proton therapy market growth. Some awareness campaigns in India focus on the importance of early detection, which leads to frequent screening and medical checkups. This proactive strategy leads to the prompt detection of cancers that can be treated with proton therapy and hence contributes to the increasing pool of patients for advanced care. In India, efforts toward making people aware about cancer and cognizant of the benefit of early detection are on a massive scale, thus propelling the growth of the proton therapy market. Large-scale cancer care centers are conducting awareness programs. For instance, in October 2024, the Apollo Cancer Centre conducted the "Men in Pink Walkathon" in Chennai, urging men to raise their voices for breast cancer screening among women in their lives. Such activities stimulate a stir about early detection, in the process creating the need for proton therapy.

Hospitals Holding the Major Shares of the Proton Therapy Market

India's hospital sector is at the forefront of the increasing demand for proton therapy as hospitals are the primary end-users of this new-generation cancer treatment. The trend is expected to continue during the forecast period with the increasing prevalence of cancer, increasing expenditure on healthcare infrastructure, and extensive adoption of new advanced medical technologies. Some of India's top hospitals, such as Apollo Cancer Care Centre, Tata Memorial Centre, and AIG Hospitals, have recently added proton therapy to their treatment facilities. These hospitals are also trying to make it more affordable so that more patients can take advantage of this new generation of technology. Launch of such specialized facilities is proving to be a key factor in improving cancer treatment outcomes in the country. Also, the Indian government is putting efforts to make proton therapy more cost-effective and available in the country. India provides this treatment at a lower cost as compared to many Western countries, which makes it a desirable choice for individuals seeking advanced cancer treatment. Moreover, the growing awareness among individuals is reflected by the rise in the number of specialized centers and government-supported schemes to make the cost more affordable. Due to this, demand for proton therapy in India is increasing at a very fast pace, driving market growth and making India one of the foremost destinations for advanced cancer treatment.

Future Market Scenario (FY2025 -FY2032F)

India's proton therapy market will experience robust growth, owing to growing adoption and expanding infrastructure. Since 2019, Apollo Proton Cancer Centre (APCC) has seen over 1,200 patients with pencil beam scanning technology for various cancers. Tata Memorial Center's government-funded center is expanding access too. Awareness, technological advancements, and government policies are primary drivers. Increasingly, proton therapy will become an established component of India's cancer care, as acceptance increases and results improve.

Furthermore, developments in India's healthcare industry and technological advancements are driving the growth of proton therapy. In January 2025, AIG Hospital in Hyderabad installed DynamicARC proton therapy, the first to be equipped in Southeast Asia. The achievement is a testament to its mission of making advanced, efficient, and affordable cancer treatment for Indian patients and setting a new benchmark in the region. Investments in cancer centers are increasing, accessibility has been enhanced, and awareness has picked up pace, driving adoption. Advanced facilities and collaborations are enhancing precision medicine, driving market expansion, and enhanced patient access.

Key Players Landscape and Outlook

The competitive landscape of proton therapy in India is changing, with significant players looking to strengthen their positions through strategic partnerships with hospitals. Proton therapy companies are raising awareness and creating more education about the benefits of proton therapy in healthcare institutions. Investments in advanced technology, expanding treatment centers, and partnerships with research organizations further drive growth. These strategies, thereby improving access in addition to developing providers as experts in their specializations, will respond to a growing demand for advanced cancer treatment in India.

In July 2023, Ion Beam Applications SA (IBA) and Apollo Proton Cancer Centre partnered to offer proton beam therapy training, and India is now the first in Southeast Asia to offer it to international oncologists. This strategic move enhances IBA's leadership in the Asian market by offering high-end proton therapy training and education programs to its customers, further cementing its dedication to innovation and excellence in cancer treatment.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. India Proton Therapy Market Outlook, FY2018-FY2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Product Type
      • 4.2.1.1. Systems
        • 4.2.1.1.1. Cyclotron
        • 4.2.1.1.2. Synchrotron
        • 4.2.1.1.3. Synchrocyclotron
      • 4.2.1.2. Services
    • 4.2.2. By Indications
      • 4.2.2.1. Head and Neck Cancer
      • 4.2.2.2. Central Nervous System Cancer
      • 4.2.2.3. Prostate Cancer
      • 4.2.2.4. Breast Cancer
      • 4.2.2.5. Lung Cancer
      • 4.2.2.6. Pediatric Cancer
      • 4.2.2.7. Gastrointestinal Cancer
      • 4.2.2.8. Others
    • 4.2.3. By Setup Type
      • 4.2.3.1. Single-Room Systems
      • 4.2.3.2. Multi-Room Systems
    • 4.2.4. By End-user
      • 4.2.4.1. Hospitals
      • 4.2.4.2. Proton Therapy Centers
      • 4.2.4.3. Cancer Centers or Institutes
    • 4.2.5. By Region
      • 4.2.5.1. North
      • 4.2.5.2. South
      • 4.2.5.3. East
      • 4.2.5.4. West and Central
    • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2024)
  • 4.3. Market Map Analysis, FY2024
    • 4.3.1. By Product Type
    • 4.3.2. By Indications
    • 4.3.3. By Setup Type
    • 4.3.4. By End-user
    • 4.3.5. By Region

5. Demand Supply Analysis

6. Import and Export Analysis

7. Value Chain Analysis

8. Porter's Five Forces Analysis

9. PESTLE Analysis

10. Pricing Analysis

11. Market Dynamics

  • 11.1. Market Drivers
  • 11.2. Market Challenges

12. Market Trends and Developments

13. Regulatory Framework and Innovation

  • 13.1. Regulatory Approvals
  • 13.2. Developments and Innovations

14. Patent Landscape

15. Case Studies

16. Competitive Landscape

  • 16.1. Competition Matrix of Top 5 Market Leaders
  • 16.2. SWOT Analysis for Top 5 Players
  • 16.3. Key Players Landscape for Top 5 Market Players
    • 16.3.1. Ion Beam Applications SA (IBA)
      • 16.3.1.1. Company Details
      • 16.3.1.2. Key Management Personnel
      • 16.3.1.3. Products and Services
      • 16.3.1.4. Financials (As Reported)
      • 16.3.1.5. Key Market Focus and Geographical Presence
      • 16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 16.3.2. Varian Medical Systems International India Pvt. Ltd.
    • 16.3.3. Mitsubishi Electric Corporation
    • 16.3.4. Hitachi Ltd.
    • 16.3.5. Elekta Medical Systems India Pvt. Ltd.
    • 16.3.6. Mevion Medical Systems, Inc.
    • 16.3.7. Optivus Proton Therapy, Inc.
    • 16.3.8. ProTom International
    • 16.3.9. Provision Solutions, LLC
    • 16.3.10. Sumitomo Heavy Industries Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

17. Strategic Recommendations

18. About Us and Disclaimer